Trial Profile
A Phase I/II Study of WT4869 in Patients with Myelodysplastic Syndromes (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs WT 4869 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 01 Dec 2017 Results published in the Cancer Science
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting.